| ISIN | CH0113817123 |
|---|---|
| Valor Number | 11381712 |
| Bloomberg Global ID | BBG0017T9CY3 |
| Fund Name | Bellevue Biotech DT CHF |
| Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
| Fund Provider | Bellevue Asset Management AG |
| Representative in Switzerland | |
| Distributor(s) |
Zürcher Kantonalbank Zürich Phone: +41 44 293 93 93 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Switzerland |
| Issuing Condition | Special conditions apply to the issue of units |
| Redemption Condition | Special conditions apply to the redemption of units |
| Investment Strategy *** | N/A |
| Peculiarities |
| Current Price * | 4,240.58 CHF | 19.11.2025 |
|---|---|---|
| Previous Price * | 4,244.86 CHF | 18.11.2025 |
| 52 Week High * | 4,244.86 CHF | 18.11.2025 |
| 52 Week Low * | 3,036.56 CHF | 10.04.2025 |
| NAV * | 4,240.58 CHF | 19.11.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 22,273,344 | |
| Unit/Share Assets *** | 4,474,735 | |
| Trading Information SIX | ||
| YTD Performance | +17.37% |
31.12.2024 - 19.11.2025
31.12.2024 19.11.2025 |
|---|---|---|
| 1 month | +6.99% |
20.10.2025 - 19.11.2025
20.10.2025 19.11.2025 |
| 3 months | +16.39% |
19.08.2025 - 19.11.2025
19.08.2025 19.11.2025 |
| 6 months | +29.51% |
19.05.2025 - 19.11.2025
19.05.2025 19.11.2025 |
| 1 year | +19.67% |
19.11.2024 - 19.11.2025
19.11.2024 19.11.2025 |
| 2 years | +37.01% |
20.11.2023 - 19.11.2025
20.11.2023 19.11.2025 |
| 3 years | +10.76% |
21.11.2022 - 19.11.2025
21.11.2022 19.11.2025 |
| 5 years | +16.48% |
19.11.2020 - 19.11.2025
19.11.2020 19.11.2025 |
| Equity Participation Rate in % | 84.42 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | 16.6695 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | 19.11.2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc | 7.66% | |
|---|---|---|
| Gilead Sciences Inc | 7.52% | |
| Amgen Inc | 7.50% | |
| Alnylam Pharmaceuticals Inc | 5.80% | |
| Regeneron Pharmaceuticals Inc | 5.38% | |
| AstraZeneca PLC ADR | 4.88% | |
| Insmed Inc | 3.43% | |
| argenx SE ADR | 2.62% | |
| Ionis Pharmaceuticals Inc | 2.08% | |
| Biogen Inc | 2.05% | |
| Last data update | 30.09.2025 | |
| TER | 1.22% |
|---|---|
| TER date | 30.09.2024 |
| Performance Fee *** | 10.00% |
| PTR | |
| Max. Management Fee *** | 1.50% |
| Ongoing Charges *** | |
|
SRRI ***
|
|
| SRRI date *** | 31.10.2025 |